HC Wainwright Has Negative Forecast for DNTH FY2024 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($3.06) per share for the year, down from their prior estimate of ($2.33). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

A number of other brokerages also recently issued reports on DNTH. Oppenheimer boosted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday. Raymond James lifted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Robert W. Baird began coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, Wedbush reduced their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Down 4.8 %

NASDAQ DNTH opened at $26.35 on Thursday. The company has a market capitalization of $779.88 million, a price-to-earnings ratio of -10.54 and a beta of 1.84. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The stock has a fifty day simple moving average of $27.70 and a 200 day simple moving average of $26.64.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares during the period. StemPoint Capital LP bought a new stake in Dianthus Therapeutics in the first quarter valued at $1,304,000. Bain Capital Life Sciences Investors LLC purchased a new stake in shares of Dianthus Therapeutics in the 1st quarter worth about $89,761,000. Janus Henderson Group PLC bought a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at about $11,251,000. Finally, RA Capital Management L.P. purchased a new position in shares of Dianthus Therapeutics during the first quarter valued at about $69,990,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.